Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Open accessThe DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Abstract
Pharmacotherapy is an effective treatment modality across psychiatric disorders. Nevertheless, many patients discontinue their medication at some point. Evidence-based guidance for patients, clinicians, and policymakers on rational discontinuation strategies is vital to enable the best, personalized treatment for any given patient. Nonetheless, there is a scarcity of guidelines on discontinuation strategies. In this perspective, we therefore summarize and critically appraise the evidence on discontinuation of six major psychotropic medication classes: antidepressants, antipsychotics, benzodiazepines, mood stabilizers, opioids, and stimulants. For each medication class, a wide range of topics pertaining to each of the following questions are discussed: (1) Who can discontinue (e.g., what are risk factors for relapse?); (2) When to discontinue (e.g., after 1 year or several years of antidepressant use?); and (3) How to discontinue (e.g., what’s the efficacy of dose reduction compared to full cessation and interventions to mitigate relapse risk?). We thus highlight how comparing the evidence across medication classes can identify knowledge gaps, which may pave the way for more integrated research on discontinuation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although our findings do cast a degree of doubt on the need for routine use of longer-term tapering regimens apart from any theoretical concerns.”
From Incidence and Nature of Antidepressant Discontinuation Symptoms (2025) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852 · cited 2×
“…for relapse following discontinuation: In bipolar disorder, young age of onset, psychotic features, numerous previous episodes, rapid cycling, comorbid anxiety, comorbid substance use, and persistent subthreshold symptoms are risk factors for recurrence, even during maintenance treatment [76].”
BackgroundSelf-citationPliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.022 · Cited by 1,545 · cited 1×
“In clinical practice, tapering stimulants is sometimes considered, while lacking evidence [139, 147].”
BackgroundSelf-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
The Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 988
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · cited 2×
“25 % a f t e r 1 y e a r [ 3 ] 3 7 – 70 % [ 47 ] F i r s t e p i s o d e o f p s y c h o s i s ( FE P ) : c o n t i n u e a t l e a s t 1 – 2 y e a r s ( w i t h r a p i d f u ll r e m i ss i o n a n d f e w r i s k f a c t o r s , d i s c o n t i n u a t i o n a f t e r 6 m o n t h s m a y b e c o…”
BackgroundInfluentialCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Long-term opioid management for chronic noncancer pain
Noble, M., Treadwell, J. R., Tregear, S. J., Coates, V. H., Wiffen, P. J., Akafomo, C., Schoelles, K. M., & Chou, R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006605.pub2 · Cited by 735
Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis
Busse, J. W., Wang, L., Kamaleldin, M., Craigie, S., Riva, J. J., Montoya, L., Mulla, S. M., Lopes, L. C., Vogel, N., Chen, E., et al. (2018) · JAMA · doi:10.1001/jama.2018.18472 · Cited by 716
Correll, C. U., Solmi, M., Croatto, G., Schneider, L. K., Rohani‐Montez, S. C., Fairley, L., Smith, N., Bitter, I., Gorwood, P., Taipale, H., et al. (2022) · World Psychiatry · doi:10.1002/wps.20994 · Cited by 686
Self-citationSelective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.19 · Cited by 567
Kuyken, W., Hayes, R., Barrett, B., Byng, R., Dalgleish, T., Kessler, D., Lewis, G., Watkins, E., Brejcha, C., Cardy, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62222-4 · Cited by 527
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Tohen, M., Frank, E., Bowden, C. L., Colom, F., Ghaemi, S. N., Yatham, L. N., Malhi, G. S., Calabrese, J. R., Nolen, W. A., Vieta, E., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00726.x · Cited by 513
Self-citationTreatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436 · cited 1×
“It is hypothesized that most DS coincide with the largest reductions in serotonin transporter (SERT) occupancy, which particularly occur at lower doses [8, 23, 24].”
BackgroundManagement of opioid use disorders: a national clinical practice guideline
Bruneau, J., Ahamad, K., Goyer, M.-È., Poulin, G., Selby, P., Fischer, B., Wild, T. C., & Wood, E. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.170958 · Cited by 412
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387 · cited 4×
“DS especially occur during treatment with SSRIs and SNRIs that have relatively short elimination half-lives ( 24 h), such as paroxetine and venlafaxine [17, 20], though other mechanisms unrelated to elimination contribute as well.”
BackgroundResultInfluentialMajor Depressive Disorder Treatment Guidelines in America and Europe
Davidson, J. R. T. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9058se1c.04gry · Cited by 344
Abdel Shaheed, C., Maher, C. G., Williams, K. A., Day, R., & McLachlan, A. J. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1251 · Cited by 342
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Opioid-Induced Tolerance and Hyperalgesia
Mercadante, S., Arcuri, E., & Santoni, A. (2019) · CNS Drugs · doi:10.1007/s40263-019-00660-0 · Cited by 326
Kaye, A. D. (2017) · Pain Physician · doi:10.36076/ppj.2017.s109 · Cited by 323
Withdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318 · cited 3×
“Even after chronic use, discontinuation over a period of less than 6 months is feasible and appropriate [95].”
BackgroundFrank, J. W., Lovejoy, T. I., Becker, W. C., Morasco, B. J., Koenig, C. J., Hoffecker, L., Dischinger, H. R., Dobscha, S. K., & Krebs, E. E. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0598 · Cited by 318 · cited 2×
“Discontinuation symptoms (DS): Opioid discontinuation in patients with chronic pain reduces pain severity and improves quality of life [116].”
BackgroundLapse and relapse following inpatient treatment of opiate dependence.
Smyth, B. P., Barry, J., Keenan, E., & Ducray, K. (2010) · PubMed · Cited by 298
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280 · cited 6×
“…symptoms (DS): DS of antidepressants include a range of somatic (e.g., nausea, dizziness) and psychological (e.g., irritability, low mood) symptoms [8], and are summarized using the FINISH acronym, which stands for Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, and…”
BackgroundMethodInfluentialAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265 · cited 4×
“Symptoms are generally mild and self-limiting [48, 73].”
BackgroundInfluentialThe benzodiazepine withdrawal syndrome
PÉTURSSON, H. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03743.x · Cited by 246 · cited 1×
“In rare instances, rapid discontinuation may induce more severe DS, including seizures and psychotic symptoms [88].”
BackgroundÁlvarez-Jiménez, M., Parker, A. G., Hetrick, S. E., McGorry, P. D., & Gleeson, J. F. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp129 · Cited by 245
Outcome After Rapid vs Gradual Discontinuation of Lithium Treatment in Bipolar Disorders
Faedda, G. L. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820180046005 · Cited by 239 · cited 2×
“Discontinuation strategies: Lithium: gradual discontinuation of lithium (at least over a month) reduces risk of DS and early recurrence relative to rapid discontinuation [74].”
BackgroundKosten, T. R., & Baxter, L. E. (2019) · The American Journal on Addictions · doi:10.1111/ajad.12862 · Cited by 235
Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis
Parr, J. M., Kavanagh, D. J., Cahill, L., Mitchell, G., & Young, R. M. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02364.x · Cited by 212
Strategies for discontinuing long-term benzodiazepine use: Meta-analysis
Voshaar, R. C. O., Couvée, J. E., Van Balkom, A. J. L. M., Mulder, P. G. H., & Zitman, F. G. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.189.3.213 · Cited by 205
Stahl, S. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0202 · Cited by 199
Kaye, A., Jones, M. R., Kaye, A., Ripoll, J. G., Galan, V., Beakley, B. D., Calixto, F., Bolden, J. L., Urman, R., & Manchikanti, L. (2017) · Pain Physician · doi:10.36076/ppj.2017.s111 · Cited by 199
Tiihonen, J., Tanskanen, A., & Taipale, H. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17091001 · Cited by 196
Self-citationVinkers, C. H., & Olivier, B. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/416864 · Cited by 195 · cited 1×
“For the sedative and anticonvulsant actions of benzodiazepines, discontinuation should commence before tolerance develops (i.e., fi rst weeks of use) [94].”
BackgroundSelf-citationMaintenance or Discontinuation of Antidepressants in Primary Care
Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106356 · Cited by 192 · cited 2×
“A landmark study pointed in the same direction in the context of primary care [16].”
BackgroundReeve, E., Ong, M., Wu, A., Jansen, J., Petrovic, M., & Gnjidic, D. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2257-8 · Cited by 192
Opioid medication discontinuation and risk of adverse opioid-related health care events
Mark, T. L., & Parish, W. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.05.001 · Cited by 180
Nolen, W. A., Licht, R. W., Young, A. H., Malhi, G. S., Tohen, M., Vieta, E., Kupka, R. W., Zarate, C., Nielsen, R. E., Baldessarini, R. J., et al. (2019) · Bipolar Disorders · doi:10.1111/bdi.12805 · Cited by 164
Self-citationBenzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management
Schweizer, E., & Rickels, K. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb05973.x · Cited by 163 · cited 1×
“DS may emerge or worsen weeks after discontinuation, with highest risks in short elimination half-life benzodiazepines (temazepam and lorazepam) [89 – 91].”
BackgroundA Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157 · cited 1×
“Discontinuation strategies: For antipsychotic discontinuation, no evidence exists that gradual tapering decreases the risk of DS, although some recommend gradual and slowly (in months, possibly hyperbolic) tapering over quicker or abrupt discontinuation (Supplementary Text) [51, 56].”
BackgroundSelf-citationGould, R. L., Coulson, M. C., Patel, N., Highton-Williamson, E., & Howard, R. J. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.126003 · Cited by 156 · cited 1×
“Multifaceted deprescribing interventions are effective in reducing benzodiaze-pine use [101].”
BackgroundHui, C. L. M., Honer, W. G., Lee, E. H. M., Chang, W. C., Chan, S. K. W., Chen, E. S. M., Pang, E. P. F., Lui, S. S. Y., Chung, D. W. S., Yeung, W. S., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30090-7 · Cited by 156
Lähteenvuo, M., Tanskanen, A., Taipale, H., Hoti, F., Vattulainen, P., Vieta, E., & Tiihonen, J. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4711 · Cited by 156
Self-citationGuidi, J., & Fava, G. A. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3650 · Cited by 155
Effectiveness of Long-Term Opioid Therapy for Chronic Non-Cancer Pain
Manchikanti, L. (2011) · Pain Physician · doi:10.36076/ppj.2011/14/e133 · Cited by 154
Conditioned Placebo Dose Reduction: A New Treatment in Attention-Deficit Hyperactivity Disorder?
Sandler, A. D., Glesne, C. E., & Bodfish, J. W. (2010) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3181e121ed · Cited by 152
Kato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0843-0 · Cited by 152 · cited 2×
“…of double-blind placebo-controlled discontinuation studies is their relatively short follow-up period (study duration averaging 40 weeks) and often rapid or abrupt antidepressant discontinuation, although the absolute relapse risk gradually decreases over time in discontinued patients [2, 15].”
BackgroundDiscontinuing antidepressant treatment in major depression.
Viguera, A. C., Baldessarini, R. J., & Friedberg, J. (1998) · Harvard Review of Psychiatry · doi:10.3109/10673229809003578 · Cited by 145
Psychosocial interventions for benzodiazepine harmful use, abuse or dependence
Darker, C. D., Sweeney, B. P., Barry, J. M., Farrell, M. F., & Donnelly-Swift, E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009652.pub2 · Cited by 142 · cited 3×
“Cognitive behavioral therapy add-on results in little added value over solely gradual dose reduction in the long run (>6 months post-intervention) [87, 100].”
BackgroundMethodDiscontinuation symptoms in depression and anxiety disorders
Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006358 · Cited by 140 · cited 1×
“[19], possibly due to smaller nocebo effects in double-blind studies and selection bias in surveys.”
BackgroundHiggins, C., Smith, B. H., & Matthews, K. (2018) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.03.009 · Cited by 130
Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
Baandrup, L., Ebdrup, B. H., Rasmussen, J. Ø., Lindschou, J., Gluud, C., & Glenthøj, B. Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011481.pub2 · Cited by 128
Mugunthan, K., McGuire, T., & Glasziou, P. (2011) · British Journal of General Practice · doi:10.3399/bjgp11x593857 · Cited by 123
Berwian, I. M., Wenzel, J. G., Collins, A. G. E., Seifritz, E., Stephan, K. E., Walter, H., & Huys, Q. J. M. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4971 · Cited by 113 · cited 1×
“Possible predictors of relapse following discontinuation are effort-reward decision time and cognitive reactivity, the latter being the most consistent predictor independent of residual symptoms [26 – 28].”
BackgroundBorges, S., Chen, Y.-F., Laughren, T. P., Temple, R., Patel, H. D., David, P. A., Mathis, M., Unger, E., Yang, P., & Khin, N. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08722 · Cited by 109
Demidenko, M. I., Dobscha, S. K., Morasco, B. J., Meath, T. H. A., Ilgen, M. A., & Lovejoy, T. I. (2017) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2017.04.011 · Cited by 109
Renoir, T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00045 · Cited by 107 · cited 1×
“However, patients and physicians are also concerned about episode recurrence and possible discontinuation symptoms (DS) [8, 9].”
BackgroundAlpha2 adrenergic agonists for the management of opioid withdrawal
Gowing, L., Farrell, M., Ali, R., & White, J. M. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002024.pub2 · Cited by 107
Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy
Tsui, J. I., Lira, M. C., Cheng, D. M., Winter, M. R., Alford, D. P., Liebschutz, J. M., Edwards, R. R., & Samet, J. H. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.06.024 · Cited by 97
Leucht, S., Bauer, S., Siafis, S., Hamza, T., Wu, H., Schneider-Thoma, J., Salanti, G., & Davis, J. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.2130 · Cited by 97
Predicting relapse after antidepressant withdrawal – a systematic review
Berwian, I. M., Walter, H., Seifritz, E., & Huys, Q. J. M. (2017) · Psychological Medicine · doi:10.1017/s0033291716002580 · Cited by 93 · cited 1×
“Risk factors for relapse or DS following discontinuation: To our knowledge, based on a systematic review, no consistent empirical evidence links patient characteristics to predicting DS, including residual symptoms, number of prior episodes, and duration of antidepressant use [25].”
BackgroundMoncrieff, J., Crellin, N., Stansfeld, J., Cooper, R., Marston, L., Freemantle, N., Lewis, G., Hunter, R., Johnson, S., Barnes, T., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00258-4 · Cited by 90
Begemann, M., Thompson, I. A., Veling, W., Gangadin, S. S., Geraets, C. N. W., Hag, E. V., Müller-Kuperus, S. J., Oomen, P. P., Voppel, A., van der Gaag, M., et al. (2020) · Trials · doi:10.1186/s13063-019-3822-5 · Cited by 89
Self-citationUhlenhuth, E. H., Balter, M. B., Ban, T. A., & Yang, K. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199912002-00005 · Cited by 80
Alvarez-Jimenez, M., O’Donoghue, B., Thompson, A., Gleeson, J. F., Bendall, S., Gonzalez-Blanch, C., Killackey, E., Wunderink, L., & McGorry, P. D. (2016) · CNS Drugs · doi:10.1007/s40263-016-0331-x · Cited by 80
Ostuzzi, G., Vita, G., Bertolini, F., Tedeschi, F., Luca, B. D., Gastaldon, C., Nosè, M., Papola, D., Purgato, M., Giovane, C. D., et al. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00158-4 · Cited by 79
Lynch, T., Ryan, C., Hughes, C. M., Presseau, J., van Allen, Z. M., Bradley, C. P., & Cadogan, C. A. (2020) · Addiction · doi:10.1111/add.14981 · Cited by 76
Griffin, M. L., Bennett, H. E., Fitzmaurice, G. M., Hill, K. P., Provost, S. E., & Weiss, R. D. (2015) · American Journal on Addictions · doi:10.1111/ajad.12188 · Cited by 75
Tani, H., Takasu, S., Uchida, H., Suzuki, T., Mimura, M., & Takeuchi, H. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0573-7 · Cited by 75
Højlund, M., Kemp, A. F., Haddad, P. M., Neill, J. C., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00078-x · Cited by 75
(2022) · doi:10.1192/bja.2021.62 · Cited by 73
Shimomura, Y., Kikuchi, Y., Suzuki, T., Uchida, H., Mimura, M., & Takeuchi, H. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.09.013 · Cited by 72
Taipale, H. T., Tanskanen, A., Correll, C. U., & Tiihonen, J. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00015-3 · Cited by 71
Self-citationBreedvelt, J. J. F., Warren, F. C., Segal, Z., Kuyken, W., & Bockting, C. L. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0823 · Cited by 68
International Consensus Statement on Major Depressive Disorder
Nutt, D. J., Davidson, J. R. T., Gelenberg, A. J., Higuchi, T., Kanba, S., Karamustafalıoğlu, O., Papakostas, G. I., Sakamoto, K., Terao, T., & Zhang, M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9058se1c.08gry · Cited by 67
Withdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Gueorguieva, R., Chekroud, A. M., & Krystal, J. H. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30038-x · Cited by 67
Antipsychotic Dosing: How Much but also How Often?
Remington, G., & Kapur, S. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq083 · Cited by 65
Ambresin, G., Palmer, V., Densley, K., Dowrick, C., Gilchrist, G., & Gunn, J. M. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.01.055 · Cited by 61
Figueroa, C. A., Ruhé, H. G., Koeter, M. W., Spinhoven, P., Van der Does, W., Bockting, C. L., & Schene, A. H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09268 · Cited by 60
Self-citationLuykx, J. J., Stam, N., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2020) · The British Journal of Psychiatry · doi:10.1192/bjp.2019.267 · Cited by 59
Self-citationBogers, J. P. A. M., Hambarian, G., Walburgh Schmidt, N., Vermeulen, J. M., & de Haan, L. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac138 · Cited by 58
Coghill, D. R., Banaschewski, T., Lecendreux, M., Johnson, M., Zuddas, A., Anderson, C. S., Civil, R., Dauphin, M., Higgins, N., Lyne, A., et al. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.01.017 · Cited by 57
Iatrogenic opioid use disorder, chronic pain and psychiatric comorbidity: A systematic review
van Rijswijk, S. M., van Beek, M. H. C. T., Schoof, G. M., Schene, A. H., Steegers, M., & Schellekens, A. F. (2019) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2019.04.008 · Cited by 57
Self-citationTakaesu, Y., Utsumi, T., Okajima, I., Shimura, A., Kotorii, N., Kuriyama, K., Yamashita, H., Suzuki, M., Watanabe, N., & Mishima, K. (2019) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2019.101214 · Cited by 57
Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis
Brandt, L., Bschor, T., Henssler, J., Müller, M., Hasan, A., Heinz, A., & Gutwinski, S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.569912 · Cited by 56
Mackey, K., Anderson, J., Bourne, D. S., Chen, E., & Peterson, K. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06253-8 · Cited by 55
Duceppe, M., Perreault, M. M., Frenette, A. J., Burry, L. D., Rico, P., Lavoie, A., Gélinas, C., Mehta, S., Dagenais, M., & Williamson, D. R. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12787 · Cited by 53
The Association between Opioid Discontinuation and Heroin Use: A Nested Case-Control Study
Binswanger, I. A., Glanz, J. M., Faul, M., Shoup, J. A., Quintana, L. M., Lyden, J., Xu, S., & Narwaney, K. J. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108248 · Cited by 53
Duration of Initial Antidepressant Treatment and Subsequent Relapse of Major Depression
Baldessarini, R. J., Lau, W. K., Sim, J., Sum, M. Y., & Sim, K. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000263 · Cited by 52
Arnold, L. E., Lindsay, R. L., Conners, C. K., Wigal, S. B., Levine, A. J., Johnson, D. E., West, S. A., Sangal, R. B., Bohan, T. P., & Zeldis, J. B. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.542 · Cited by 51
Kishi, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N. (2021) · Psychological Medicine · doi:10.1017/s0033291720003505 · Cited by 48
Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study
Biel, M. G., Peselow, E., Mulcare, L., Case, B. G., & Fieve, R. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00389.x · Cited by 47
Quilichini, J.-B., Revet, A., Garcia, P., Bouquié, R., Hamard, J., Yrondi, A., & Montastruc, F. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.041 · Cited by 47
Rasmussen, A. F., Poulsen, S. S., Oldenburg, L. I. K., & Vermehren, C. (2021) · Metabolites · doi:10.3390/metabo11040254 · Cited by 39
Benzodiazepine deprescription strategies in chronic users: a systematic review
Ribeiro, P. R. D. S., & Schlindwein, A. D. (2021) · Family Practice · doi:10.1093/fampra/cmab017 · Cited by 39
(2010) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20100730-04 · Cited by 38
Antidepressant Dose Reduction and the Risk of Relapse in Major Depressive Disorder
Papakostas, G. I., Perlis, R. H., Seifert, C., & Fava, M. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000104702 · Cited by 38
Brouillet, E., Chavoix, C., Bottlaender, M., Khalili-Varasteh, M., Hantraye, P., Fournier, D., Dodd, R. H., & Mazière, M. (1991) · Brain Research · doi:10.1016/0006-8993(91)90131-e · Cited by 37
Intentional Discontinuation of Psychostimulants Used to Treat ADHD in Youth: A Review and Analysis
Lohr, W. D., Wanta, J. W., Baker, M., Grudnikoff, E., Morgan, W. S., Chhabra, D., & Lee, T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.642798 · Cited by 36
Omachi, Y., & Sumiyoshi, T. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00447 · Cited by 35
Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis
Brandt, L., Schneider‐Thoma, J., Siafis, S., Efthimiou, O., Bermpohl, F., Loncar, L., Neumann, K., Hasan, A., Heinz, A., Leucht, S., et al. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00014-1 · Cited by 35
Long-Term Treatment of Depression with Antidepressants: A Systematic Narrative Review
Furukawa, T. A., Cipriani, A., Barbui, C., & Geddes, J. R. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/070674370705200902 · Cited by 33
Opioid Use 12 Months Following Interdisciplinary Pain Rehabilitation with Weaning
Huffman, K. L., Sweis, G. W., Gase, A., Scheman, J., & Covington, E. C. (2013) · Pain Medicine · doi:10.1111/pme.12201 · Cited by 33
Campbell, G., Bruno, R., Darke, S. G., & Degenhardt, L. J. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.05.004 · Cited by 33
Intermittent medication ‐ an alternative?
Gäebel, W. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05863.x · Cited by 33
Tapering opioids: a comprehensive qualitative review
Davis, M. P., Digwood, G., Mehta, Z., & McPherson, M. L. (2020) · Annals of Palliative Medicine · doi:10.21037/apm.2019.12.10 · Cited by 33
Impact of adherence to antidepressants on long-term prescription opioid use cessation
Scherrer, J. F., Salas, J., Sullivan, M. D., Ahmedani, B. K., Copeland, L. A., Bucholz, K. K., Burroughs, T., Schneider, F. D., & Lustman, P. J. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2017.25 · Cited by 31
Antidepressants, withdrawal, and addiction; where are we now?
Jauhar, S., Hayes, J., Goodwin, G. M., Baldwin, D. S., Cowen, P. J., & Nutt, D. J. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845799 · Cited by 31
Self-citationTsujii, N., Okada, T., Usami, M., Kuwabara, H., Fujita, J., Negoro, H., Kawamura, M., Iida, J., & Saito, T. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19r13015 · Cited by 31 · cited 1×
“Risk factors for relapse following discontinuation: Re-emergence of ADHD symptoms is independent of age and sex, although adults may be at less risk compared to minors after stimulant discontinuation [139, 144].”
BackgroundKhan, A., Musgnung, J., Ramey, T., Messig, M., Buckley, G., & Ninan, P. T. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000100 · Cited by 30
Tapering antipsychotic medication: practical considerations
Horowitz, M. A., Moncrieff, J., de Haan, L., Bogers, J. P. A. M., Gangadin, S. S., Kikkert, M., Veling, W., & Sommer, I. E. (2021) · Psychological Medicine · doi:10.1017/s0033291721003299 · Cited by 30
Self-citationde Vries, C., van Bergen, A., Regeer, E. J., Benthem, E. M., Kupka, R., & Boks, M. P. (2013) · Bipolar Disorders · doi:10.1111/bdi.12105 · Cited by 28
Self-citationWeller, A., Gleeson, J., Álvarez‐Jiménez, M., McGorry, P. D., Nelson, B., Allott, K., Bendall, S., Bartholomeusz, C., Koval, P., Harrigan, S., et al. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12769 · Cited by 28
Tapering of SSRI treatment to mitigate withdrawal symptoms
Ruhe, H. G., Horikx, A., van Avendonk, M. J. P., Groeneweg, B. F., & Woutersen-Koch, H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30182-8 · Cited by 28
Self-citationGallo, A. T., & Hulse, G. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120981390 · Cited by 28
Oh, J., Nam, H., Park, S. M., Chae, J., & Kim, T. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.01.006 · Cited by 28
How to reduce and stop psychiatric medication
Horowitz, M. A., & Taylor, D. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.001 · Cited by 26 · cited 1×
“At the same time, it is also clear that both the quantity and quality of discontinuation evidence is not only heterogeneous, but also quite limited [155].”
BackgroundJobert, A., Laforgue, E.-J., Grall-Bronnec, M., Rousselet, M., Péré, M., Jolliet, P., FAN-Network, Barjoux, C., Batisse, A., Boucher, A., et al. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03007-7 · Cited by 24 · cited 1×
“[84, 85].”
de Klerk‐Sluis, J. M., Huijbers, M. J., Löcke, S., Spijker, J., Spinhoven, P., Speckens, A. E. M., & Ruhé, H. G. (2021) · Depression and Anxiety · doi:10.1002/da.23220 · Cited by 24
Self-citationAdverse events after antipsychotic discontinuation: an individual participant data meta-analysis.
Brandt, L., Schneider‐Thoma, J., Siafis, S., Efthimiou, O., Bermpohl, F., Loncar, L., Neumann, K., Hasan, A., Heinz, A., Leucht, S., et al. (2022) · doi:10.48350/165893 · Cited by 24
Jauhar, S., & Hayes, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.01.025 · Cited by 23 · cited 2×
“DS in SSRIs were found to be higher in both surveys of selected populations and open-label studies [17, 18] (55%), than in double-blind studies (30”
BackgroundResultSelf-citationGallagher, J. C., Strzinek, R. A., Cheng, R.-F. J., Ausmanas, M. K., Astl, D., & Seljan, P. (2012) · Journal of Women's Health · doi:10.1089/jwh.2011.2764 · Cited by 21
Brandt, L., Ritter, K., Schneider‐Thoma, J., Siafis, S., Montag, C., Ayrilmaz, H., Bermpohl, F., Hasan, A., Heinz, A., Leucht, S., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00008-1 · Cited by 21
Holm, M., Tanskanen, A. J., Lähteenvuo, M., Tiihonen, J., & Taipale, H. T. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.05.012 · Cited by 20
Self-citationWentink, C., Huijbers, M. J., Lucassen, P. L., van der Gouw, A., Kramers, C., Spijker, J., & Speckens, A. E. (2019) · British Journal of General Practice · doi:10.3399/bjgp19x706001 · Cited by 19 · cited 1×
“…decision-making is essential for the success of the discontinuation strategy, tailoring decisions to individual patient needs, abiding by informed consent procedures and empowering a patient ’ s autonomy, while at the same time carefully weighing in the harm/bene fi t ratio of discontinuation [152].”
BackgroundDeprescribing practices in Canada: A scoping review
Desai, M., & Park, T. (2022) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635221114114 · Cited by 19
Murru, A., Colom, F., Nivoli, A., Pacchiarotti, I., Valentí, M., & Vieta, E. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.09.012 · Cited by 17
Self-citationMinegishi, T., Garrido, M. M., Stein, M. D., Oliva, E. M., & Frakt, A. B. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06252-9 · Cited by 16
Samalin, L., & Belzeaux-R, R. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.04.012 · Cited by 16
Zeiner, P. (1999) · Nordic Journal of Psychiatry · doi:10.1080/080394899426738 · Cited by 14
Inoue, Y., Takaesu, Y., & Koebis, M. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03196-0 · Cited by 14
Tint, A., Haddad, P. M., & Anderson, I. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107087488 · Cited by 13
[Summary of the Dutch College of General Practitioners' practice guideline 'Depression'].
van Avendonk, M. J., van Weel-Baumgarten, E. M., van der Weele, G. M., Wiersma, T., & Burgers, J. S. (2012) · PubMed · Cited by 13
Bienek, N., Maier, C., Kaisler, M., Michel‐Lauter, B., Schwarzer, A., & Meyer‐Frießem, C. H. (2018) · Pain Medicine · doi:10.1093/pm/pny320 · Cited by 13
Hamlet’s augury: how to manage discontinuation of mood stabilizers in bipolar disorder
Qureshi, M. M., & Young, A. H. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211000612 · Cited by 13
Liu, C., Hsieh, M. H., Chien, Y., Liu, C., Lin, Y., Hwang, T., & Hwu, H. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13144 · Cited by 12
Basińska-Szafrańska, A. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03205-x · Cited by 12
Quinn, P. D., Chang, Z., Bair, M. J., Rickert, M. E., Gibbons, R. D., Kroenke, K., & D'Onofrio, B. M. (2021) · Pain · doi:10.1097/j.pain.0000000000002415 · Cited by 11
Antidepressant Discontinuation: In Need of Scientific Evidence
Vinkers, C. H., Ruhé, H. G., & Penninx, B. W. J. H. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001460 · Cited by 11
Self-citationTapering Opioid Therapy: Clinical Strategies
Pergolizzi, J. V., Rosenblatt, M., Mariano, D. J., & Bisney, J. (2018) · Pain Management · doi:10.2217/pmt-2018-0040 · Cited by 9
MacDonald, T., Gallo, A. T., Basso-Hulse, G., & Hulse, G. K. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109517 · Cited by 7
A shared decision journey to bridge the gap between treatment recommendation and low adherence?
Grootens, K. P., & Verwijmeren, D. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.01.007 · Cited by 4
Entzugssyndrom nach dem Absetzen von Lithium – Eine systematische Literaturübersicht
Gutwinski, S., Fierley, L., Schreiter, S., Bermpohl, F., Heinz, A., & Henssler, J. F. (2021) · Psychiatrische Praxis · doi:10.1055/a-1481-1953 · Cited by 1
Research works printed but not linked: 3
- Tripp CC, Rak E, Burker E. A review of effective treatments for patients with co-occurring chronic pain and opioid addiction. VISTAS Online. 2017.
- Howland RH. Potential adverse effects of discontinuing psychotropic drugs. J Psychosoc Nurs Ment health Serv. 2010;48:11–4.
- National Guideline Centre (UK). Withdrawal from pharmacological treatment and drug holidays: attention deficit hyperactivity disorder: diagnosis and management: evidence review I. London: National Institute for Health and Care Excellence (NICE); 2018.
Cited by
Incidence and Nature of Antidepressant Discontinuation Symptoms
Kalfas, M., Tsapekos, D., Butler, M., McCutcheon, R. A., Pillinger, T., Strawbridge, R., Bhat, B. B., Haddad, P. M., Cowen, P. J., Howes, O. D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1362 · Cited by 42
Self-citationFung, C. H., Alessi, C., Martin, J. L., Josephson, K. R., Kierlin, L., Dzierzewski, J. M., Moore, A. A., Badr, M. S., Zeidler, M. R., Kelly, M. R., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.5020 · Cited by 28
Costa, B., & Vale, N. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154398 · Cited by 22
Photodegradation of typical psychotropic drugs in the aquatic environment: a critical review
Wang, C., Guo, R., Guo, C., Yin, H., & Xu, J. F. (2025) · Environmental Science Processes & Impacts · doi:10.1039/d4em00669k · Cited by 13
Montégut, L., Rousseau, A., Ungolo, C., Derosa, L., Fidelle, M., Alves Costa Silva, C., Routy, B., Zitvogel, L., Besse, B., Pasolli, E., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2528955 · Cited by 8
“44,45 Beyond the epidemiological association between benzodiazepine use and reduced efficacy of immunotherapy, the present study reveals a correlation between benzodiazepine consumption and stigmata of intestinal dysbiosis.”
Metadata
- Authors
- Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., Tiihonen, J., Veldman, S. E., Veling, W., Vis, R., de Wit, L. E., & Luykx, J. J.
- Affiliations
- Amsterdam Neuroscience (NL)
- Radboud University Nijmegen (NL)
- King's College London (GB)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- University of Helsinki (FI)
- University Medical Center Groningen (NL)
- St. Antonius Ziekenhuis (NL)
- Maastricht University Medical Centre (NL)
- Corresponding author
- Vinkers, Christiaan H.
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2024-03-19
- Volume
- 29
- Issue
- 8
- Pages
- 2575-2586
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC11412909
- OpenAlex
- W4392956861
- Cited by
- 51
- References
- 154
- Citations by year
- 2026: 32 · 2025: 13 · 2024: 5
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Työväentutkimus Vuosikirja (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Biogen
- Sunovion
- Wellcome Trust
- ZonMw
- Dainippon Sumitomo Pharma
- Gedeon Richter
- Shionogi
- Hersenstichting
- H. Lundbeck A/S
- Idorsia Pharmaceuticals
- HLS Therapeutics
- Cilag
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressants, antipsychotic drugs, benzodiazepines, mood stabilizers, opioids, stimulants, relapse risk, dose reduction, tapering, treatment duration, psychopharmacological treatment
- MeSH terms
- Antidepressive Agents, Mental Disorders, Benzodiazepines, Humans, Psychotropic Drugs, Recurrence, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.